Evidence map›Paper›PMID 29568102›Full record

ArticleInternational journal of obesity (2005)2018

Enhanced hexose-6-phosphate dehydrogenase expression in adipose tissue may contribute to diet-induced visceral adiposity.

Limei Liu, Ying Wang, Jian Wang, Yunzhou Dong, Scarlett Chang, Xiwen Liu, Kabirullah Lutfy, Hong Chen, Theodore C Friedman, Meisheng Jiang and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in International journal of obesity (2005), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Adipocyte · 2021
    Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 7 institutions in 2 countries.

Limei LiuDivision of Endocrinology, Metabolism & Molecular Medicine, Charles R. Drew University of Medicine & Sciences, David Geffen School of Medicine, University of California, 1731 E. 120th St, Los Angeles, CA, 90059, USA.
Ying WangDivision of Endocrinology, Metabolism & Molecular Medicine, Charles R. Drew University of Medicine & Sciences, David Geffen School of Medicine, University of California, 1731 E. 120th St, Los Angeles, CA, 90059, USA.
Jian WangDivision of Endocrinology, Metabolism & Molecular Medicine, Charles R. Drew University of Medicine & Sciences, David Geffen School of Medicine, University of California, 1731 E. 120th St, Los Angeles, CA, 90059, USA.
Yunzhou DongVascular Biology Program, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
Scarlett ChangDivision of Endocrinology, Metabolism & Molecular Medicine, Charles R. Drew University of Medicine & Sciences, David Geffen School of Medicine, University of California, 1731 E. 120th St, Los Angeles, CA, 90059, USA.
Xiwen LiuDivision of Endocrinology, Metabolism & Molecular Medicine, Charles R. Drew University of Medicine & Sciences, David Geffen School of Medicine, University of California, 1731 E. 120th St, Los Angeles, CA, 90059, USA.
Kabirullah LutfyDepartment of Endocrinology & Metabolism, Shanghai Jiaotong University Affiliated Sixth People's Hospital, Shanghai Diabetes Institute, Shanghai, People's Republic of China.
Hong ChenVascular Biology Program, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
Theodore C FriedmanDivision of Endocrinology, Metabolism & Molecular Medicine, Charles R. Drew University of Medicine & Sciences, David Geffen School of Medicine, University of California, 1731 E. 120th St, Los Angeles, CA, 90059, USA.
Meisheng JiangDepartment of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, CA, 90095, USA.
Yanjun LiuDivision of Endocrinology, Metabolism & Molecular Medicine, Charles R. Drew University of Medicine & Sciences, David Geffen School of Medicine, University of California, 1731 E. 120th St, Los Angeles, CA, 90059, USA. dryanjunliu@hotmail.com.
Charles R. Drew University of Medicine and Science · USBoston Children's Hospital · USFirst Hospital of Jilin University · CNHarvard University · USJilin University · CNShanghai Sixth People's Hospital · CNUniversity of California, Los Angeles · US

Funding

Epsin in Angiogenesis and Vascular RemodelingR01HL093242 · NHLBI · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI CHEN, HONG, WANG, DA-ZHI · 2009 to 2021
$7.3M
Molecular Mechanisms Controlling Lymphatic Vascular Function in Health and DiseaseR01HL133216 · NHLBI · BOSTON CHILDREN'S HOSPITAL · PI CHEN, HONG, DIXON, JAMES BRANDON · 2016 to 2025
$6.7M
Drew MIDARP (Infrastructure in Drug Abuse Research)R24DA017298 · NIDA · CHARLES R. DREW UNIVERSITY OF MED &SCI · PI FRIEDMAN, THEODORE C · 2004 to 2018
$5.0M
Mechanisms regulating VEGF receptors in diabetic angiogenesisR01HL130845 · NHLBI · BOSTON CHILDREN'S HOSPITAL · PI CHEN, HONG, XU, JIAN · 2016 to 2023
$4.9M
Molecular Mechanisms Regulating Endothelial DysfunctionR01HL137229 · NHLBI · BOSTON CHILDREN'S HOSPITAL · PI CHEN, HONG, SRIVASTAVA, SANJAY · 2017 to 2020
$2.7M
The Role of Adipose H6PDH in Type 2 Diabetes and ObesitySC1DK104821 · NIDDK · CHARLES R. DREW UNIVERSITY OF MED & SCI · PI LIU, YANJUN · 2014 to 2017
$1.3M
NHLBI NIH HHS R01 HL093242NHLBI NIH HHS R01 HL130845NHLBI NIH HHS R01 HL133216NHLBI NIH HHS R01 HL137229NIDA NIH HHS R24 DA017298NIDDK NIH HHS SC1 DK104821
6 · The paper itself

Abstract

backgroundVisceral fat accumulation increases the risk of developing type 2 diabetes and metabolic syndrome, and is associated with excessive glucocorticoids (GCs). Fat depot-specific GC action is tightly controlled by 11ß-hydroxysteroid dehydrogenase (11ß-HSD1) coupled with the enzyme hexose-6-phosphate dehydrogenase (H6PDH). Mice with inactivation or activation of H6PDH genes show altered adipose 11ß-HSD1 activity and lipid storage. We hypothesized that adipose tissue H6PDH activation is a leading cause for the visceral obesity and insulin resistance. Here, we explored the role and possible mechanism of enhancing adipose H6PDH in the development of visceral adiposity in vivo.

methodsWe investigated the potential contribution of adipose H6PDH activation to the accumulation of visceral fat by characterization of visceral fat obese gene expression profiles, fat distribution, adipocyte metabolic molecules, and abdominal fat-specific GC signaling mechanisms underlying the diet-induced visceral obesity and insulin resistance in H6PDH transgenic mice fed a standard of high-fat diet (HFD).

resultsTransgenic H6PDH mice display increased abdominal fat accumulation, which is paralleled by elevated lipid synthesis associated with induction of lipogenic transcriptor C/EBPα and PPARγ mRNA levels within adipose tissue. Transgenic H6PDH mice fed a high-fat diet (HFD) gained more abdominal visceral fat mass coupled with activation of GSK3β and induction of XBP1/IRE1α, but reduced pThr

conclusionThese data provide the first in vivo mechanistic evidence for the adverse metabolic effects of adipose H6PDH activation on visceral fat distribution, fat metabolism, and adipocyte function through enhancing 11ß-HSD1-driven intra-adipose GC action.

Indexed as

AdipocytesAdipose TissueAnimalsCarbohydrate DehydrogenasesDiet, High-FatMaleMiceMice, TransgenicObesity, AbdominalTranscriptomeCarbohydrate Dehydrogenasesgalactose-6-phosphate dehydrogenase

Identifiers

PMID29568102
PMCPMC6105561
OpenAlexW2792718510

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.